Post-radiation targeting of TIGIT and CD96 improved immunotherapy efficacy in head and neck squamous cell carcinoma
Our findings suggest that TIGIT and CD96 could be markers of the clinical stage and treatment response of HNSCC. Therefore, administering anti-TIGIT and anti-CD96 after radiotherapy may provide a novel approach for incorporating immunoradiotherapy into HNSCC treatment.
Authors
- Yasuyuki SHIMIZU (ORCID: https://orcid.org/0000-0002-1870-5741)
- Ryohei Sasaki (ORCID: https://orcid.org/0000-0002-4994-9386)
- Mohammed Salah (ORCID: https://orcid.org/0000-0003-2814-0809)
- Naritoshi Mukumoto
- Yoshiko Fujita (ORCID: https://orcid.org/0000-0002-4472-4102)
- Hirotaka Shinomiya (ORCID: https://orcid.org/0000-0003-1667-7545)
- Joji Kotani (ORCID: https://orcid.org/0000-0003-0808-095X)
- Daisuke Miyawaki
- Takeaki Ishihara
- Hiroki Kawaguchi (ORCID: https://orcid.org/0000-0003-4367-581X)
- Masafumi Saito
- Nen-Ichi Nibu
Institutions
- South Valley University (EG)
- National Defense Medical College (JP)
- Kobe University (JP)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1186/s10020-025-01409-w
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.80